📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

AML-399 A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML) (2022)

First Author: Vyas P

Attributed to: University of Oxford – Confidence in Concept 2019 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2152-2650(22)01288-5

Publication URI: https://api.elsevier.com/content/abstract/scopus_id/85138168649

Type: Journal Article/Review

Parent Publication: Clinical Lymphoma Myeloma and Leukemia